Peter C Taylor
Roy Fleischmann
Tsutomu Takeuchi
Janet Pope
Mark C Genovese
Baojin Zhu
Carol Gaich
Xiang Zhang
Christina Dickson
Amanda Quebe
Francesco De Leonardis
Anabela Cardoso
Ilias Kouris
Patrick Durez
Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Science, Oxford University, Oxford, UNITED KINGDOM
Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
Department of Internal Medicine Division of Rheumatology, Tokai University School of Medicine, Isehara, Japan
Division of Rheumatology, Joseph’s Health Care, London, London, ON, CANADA
Department of Medicine - Immunology & Rheumatology, Stanford University Medical Center, Palo Alto, CA
Real-World Analytics-Immunology, Eli Lilly & Company, Indianapolis, IN
Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN
Eli Lilly and Company, Indianapolis, IN
Department of Medicine, Eli Lilly & Company, Indianapolis, IN
Department of Rheumatology, Eli Lilly & Company, Indianapolis, IN
Department of Rheumatology, Eli Lilly & Company, Indianapolis, IN
Department of Rheumatology, Eli Lilly & Company, Indianapolis, IN
Department of Rheumatology, Eli Lilly & Company, Indianapolis, IN
Department of Rheumatology, Université Catholique de Louvain and Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Brussels, BELGIUM
United Kingdom
United States
Japan
Canada
Belgium
N/A
Autoimmune (AI)
Rheumatoid arthritis
Tumor necrosis factor
Methotrexate
Baricitinib
Adalimumab
BARI
N/A
Randomized
Placebo Control
NA
N/A
N/A
N/A